Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/25/2010DE102010007381A1 Prophylaxemittel gegen Krebskrankheiten und erhöhte Hautspannungen Prophylaxis for cancer diseases and increased skin tension
11/25/2010DE102009022424A1 Dimethylglycine in dimethylglycine pangamic acid is transported using a sodium chloride carrier and L-lysine bypassing the first pass effect in the internal organs such as lung and heart, useful as biochemical-pharmaceutical drug
11/25/2010CA2819700A1 N- [(2'r) -2'-deoxy-2'-fluoro-2' -methyl-p-phenyl-5' -uridylyl] -l-alanine 1-methylethyl ester and process for its production
11/25/2010CA2816448A1 Treatment of heart failure with normal ejection fraction
11/25/2010CA2795981A1 Compositions and methods for increasing telomerase activity
11/25/2010CA2763156A1 Identification of micro-rnas involved in post-myocardial infarction remodeling and heart failure
11/25/2010CA2763151A1 N- [(2'r) -2'-deoxy-2'-fluoro-2' -methyl-p-phenyl-5' -uridylyl] -l-alanine 1-methylethyl ester and process for its production
11/25/2010CA2763122A1 Bimacrocyclic hcv ns3 protease inhibitors
11/25/2010CA2763099A1 Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
11/25/2010CA2763016A1 Targeting micrornas for metabolic disorders
11/25/2010CA2762989A1 Application and uses of prg4 and therapeutic modulation thereof
11/25/2010CA2762987A1 Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
11/25/2010CA2762939A1 Self-emulsifying composition of .omega.3 fatty acid
11/25/2010CA2762813A1 Use of inhibitors of zdhhc2 activity for modulation of adipogenesis
11/25/2010CA2762805A1 1,4-dihydropyridine derivatives and their uses
11/25/2010CA2762640A1 Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
11/25/2010CA2762600A1 Use of dynamin ring stabilizers
11/25/2010CA2762577A1 Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl)pyridine and their therapeutical uses
11/25/2010CA2762527A1 Isoxazolines as inhibitors of fatty acid amide hydrolase
11/25/2010CA2762427A1 Nitrile derivatives and their pharmaceutical use and compositions
11/25/2010CA2762394A1 Topical retinoid solutions
11/25/2010CA2762391A1 Liquid dosage forms of isotretinoin
11/25/2010CA2762388A1 Oral compositions of celecoxib
11/25/2010CA2762369A1 Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
11/25/2010CA2762351A1 Treatment of muscle disease characterized by insulin resistance
11/25/2010CA2762336A1 Solid pharmaceutical compositions and processes for their production
11/25/2010CA2762313A1 Pyrazolopyrimidines and related heterocycles as kinase inhibitors
11/25/2010CA2762233A1 Anticancer compound and pharmaceutical composition containing the same
11/25/2010CA2762232A1 Substituted quinolines for use as vegf inhibitors
11/25/2010CA2762226A1 Isoquinolin-1 (2h) -one derivatives as parp-1 inhibitors
11/25/2010CA2762212A1 Elastin for soft tissue augmentation
11/25/2010CA2762176A1 Marker differentially expressed in cancer stem cells and methods of using same
11/25/2010CA2762174A1 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
11/25/2010CA2762159A1 The improvement of gastrointestinal health, immunity and performance by dietary intervention
11/25/2010CA2762095A1 Compositions comprising cationic amphiphiles and colipids for delivering therapeutics molecules
11/25/2010CA2761961A1 Modulators of 5-ht receptors and methods of use thereof
11/25/2010CA2761954A1 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
11/25/2010CA2761762A1 Serotonin 5-ht3 receptor antagonists for use in the treatment of lesional vestibular disorders
11/25/2010CA2761624A1 Compositions for continuous administration of dopa decarboxylase inhibitors
11/25/2010CA2761576A1 Oral suspension comprising telmisartan
11/25/2010CA2761499A1 A3 adenosine receptor agonists for the reduction of intraocular pressure
11/25/2010CA2761279A1 Heterocyclic antiviral compounds
11/25/2010CA2761254A1 Anti-inflammatory composition containing macrolactin a and a derivative thereof as active ingredients
11/25/2010CA2760940A1 Methods of modulating uric acid levels
11/25/2010CA2760779A1 Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
11/25/2010CA2760766A1 Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
11/25/2010CA2760765A1 Disaccharin, difumaric acid, di-1-hydroxy-2-naphthoic acid and mono-benzoic acid salts of 4- (dimethylamino)butyl 2- (4- ( (2-amino-4-methyl-6- (pentylamino) pyrimidin-5-yl) methyl) phenyl)acetate
11/25/2010CA2760130A1 Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof
11/25/2010CA2759674A1 Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility
11/25/2010CA2758222A1 Protease inhibitors
11/25/2010CA2757838A1 Synthetic endoxifen for treating mammalian diseases
11/25/2010CA2753560A1 Inhibitors of phosphatidylinositol 3-kinase
11/25/2010CA2752550A1 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
11/24/2010EP2253705A1 Use of inhibitors of Zdhhc2 activity for modulation of adipogenesis
11/24/2010EP2253639A1 Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
11/24/2010EP2253636A1 Neuronal cell death inhibitor
11/24/2010EP2253633A1 Fused heterocyclic compound
11/24/2010EP2253632A1 Pyrazolopyramidinone derivatives, their preparation and their use
11/24/2010EP2253631A1 Spyrocyclic quiniclidinic ether derivatives
11/24/2010EP2253630A1 Heterocyclic compound and use thereof
11/24/2010EP2253629A1 Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
11/24/2010EP2253627A1 Inclusion complex of raloxifene hydrochloride and beta-cyclodextrin.
11/24/2010EP2253625A1 Pyridazinones, the preparation and the use thereof
11/24/2010EP2253621A1 A set of geldanamycin derivatives and their preparation methods
11/24/2010EP2253620A1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
11/24/2010EP2253618A1 Compound having 6-membered aromatic ring
11/24/2010EP2253617A1 Halogenated compounds as pesticides
11/24/2010EP2253616A1 Process for the preparation of compounds capable of activating cholinergic receptors
11/24/2010EP2253614A1 Inhibitors of IAP
11/24/2010EP2253612A1 Organic compounds
11/24/2010EP2253333A2 Contrast Agents for Myocardial Perfusion Imaging
11/24/2010EP2253329A1 Ibuprofen lysinate oral suspension
11/24/2010EP2253327A1 Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound
11/24/2010EP2253325A1 Agent for enhancing corneal epithelial barrier function
11/24/2010EP2253322A1 Method and composition containing latanoprost for treating ocular hypertension and glaucoma
11/24/2010EP2253321A1 Collyrium for the treatment of conial cornea with "cross-linking" trans-epithelial technique
11/24/2010EP2253320A1 Combination of a pyrimidylaminobenzamide and a mTOR kinase inhibitor
11/24/2010EP2253319A1 Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
11/24/2010EP2253318A1 Improvement of dissolvability of preparation containing olmesartan medoxomil
11/24/2010EP2253317A2 Triazol compounds for treating biofilm formation
11/24/2010EP2253316A1 serotonin 5-HT3 receptor antagonists for use in the treatment or prevention of vestibular deficits
11/24/2010EP2253315A1 Alkoxyphenylpropanoic acid derivatives
11/24/2010EP2253314A2 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
11/24/2010EP2253313A1 Tranilast as modulator of T cell functioning for use in the treatment of autoimmune diseases
11/24/2010EP2253312A2 Use of osmolytes obtained from extremophilic bacteria for the preparation of inhalable medicaments for the prophylaxis and treatment of pulmonary and cardiovascular diseases and an inhalation device containing osmolytes as active agents
11/24/2010EP2253311A2 Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto
11/24/2010EP2253310A1 Sustained release pharmaceutical formulation comprising phenylephrine
11/24/2010EP2253309A2 Gastric acid secretion inhibiting composition
11/24/2010EP2253308A1 Pharmaceutical composition comprising microbubbles for targeted tumor therapy
11/24/2010EP2253307A1 L-Carnitin for supression of crystallisation
11/24/2010EP2253266A1 Method for treating patients with cerebral calcifications
11/24/2010EP2253228A2 Composition for controlling and improving female and male gametogenesis
11/24/2010EP2253223A1 Package drink
11/24/2010EP2252706A2 Slit2 cancer markers
11/24/2010EP2252703A2 Disease markers and uses thereof
11/24/2010EP2252690A2 Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
11/24/2010EP2252688A1 Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
11/24/2010EP2252636A1 Modalmetric fibre sensor
11/24/2010EP2252635A2 Carrageenan modified by ion-exchange process
11/24/2010EP2252619A1 Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
1 ... 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 ... 7860